RenovoRx Announces $10 Million Financing for Innovative Treatment for Advanced Pancreatic Cancer
Company’s RenovoCath System Has Received Orphan Drug Designation from the FDA for its Innovative Approach. LOS ALTOS, Calif. – May 23, 2018 – RenovoRx, Inc., a medical technology company developing…
Read More